This prospective case-control study investigated the potential of circulating cell-free DNA (cfDNA) as a non-invasive biomarker for ovarian cancer. Researchers quantified cfDNA levels in 50 ovarian cancer patients, 50 patients with benign ovarian lesions, and 50 controls. Results revealed significantly higher cfDNA levels in the malignant group. cfDNA demonstrated strong discriminatory capability for predicting ovarian cancer, its late stage, and mortality, with high AUC values. The study concludes that cfDNA could serve as a diagnostic and prognostic biomarker for ovarian cancer, supporting its use in risk stratification and treatment planning.
The phase 3 KEYLYNK-001 (ENGOT-OV43/GOG-3036) trial investigated the efficacy and safety of pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance as first-line treatment for patients with advanced BRCA1/2 non-mutated epithelial ovarian cancer. The study randomized 1367 patients into three arms: pembrolizumab-olaparib, pembrolizumab alone, or placebo, all combined with initial chemotherapy. Results demonstrated a significant improvement in progression-free survival for the pembrolizumab-olaparib group compared to the control, both in the PD-L1 CPS ≥10 and intention-to-treat populations. This combination regimen suggests a potential new therapeutic option for this patient population.
This study investigated non-parametric differential methylation analysis to characterize histotype-specific promoter regions in early-stage epithelial ovarian cancer (EOC). The aim was to identify candidate epigenetic biomarkers for diagnosis and histotype stratification. Researchers applied this approach to an EOC cohort and compared results with existing programs. The identified promoter regions were highly reproducible and effectively stratified EOC histotypes in external cohorts through predictive classification. The study also revealed differences in methylation distribution types among histotypes, suggesting that methods sensitive to non-normally distributed data might be poorly suited for comparing groups with different distribution types.
This study identified a novel gene expression signature predictive of bevacizumab response in ovarian cancer patients. Utilizing machine learning approaches on RNA-seq and microarray data, researchers discovered a signature associated with significantly improved overall survival in patients receiving bevacizumab. This signature, potentially linked to stemness-like features and the CTCFL gene, was validated across multiple independent cohorts. These findings suggest transcriptional heterogeneity in ovarian cancer beyond current classifications, offering a pathway for improved patient selection.
This nationwide Japanese study resolved the status of the BRCA2 c.7847C>T (p.Ser2616Phe) variant, which is specific to the Japanese population and was previously of uncertain significance. By integrating quantitative cosegregation analyses, robust functional evidence, and population frequency data, researchers accumulated strong evidence. The evaluation led to the reclassification of this variant as "Pathogenic" according to the ClinGen ENIGMA framework. This reclassification is crucial for ensuring eligible Japanese patients gain access to appropriate targeted therapies, such as PARP inhibitors.
This study aimed to develop a mutational signature-based biomarker (MSBM) to define homologous recombination deficiency (HRD) in advanced ovarian cancer, overcoming limitations of genomic scar-based assays. The MSBM integrates tumor-BRCA mutation status, Mutational Signature 3 similarity score, and the absence of CCNE1 amplification, derived from whole-exome sequencing. A phase II trial (MSBM-OL) validated this biomarker and evaluated the efficacy of olaparib maintenance monotherapy in HRD-positive patients. The study demonstrated that olaparib significantly extended progression-free survival (22.3 months) compared to a predefined 9-month threshold, confirming its clinical benefit as first-line maintenance therapy.